Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(23), P. 7306 - 7306
Published: Dec. 1, 2024
Anemia is a prevalent comorbidity of diabetes, and although various mechanisms have been shown to link these two conditions, their interaction has not sufficiently explored. Our cross-sectional, non-interventional study aimed evaluate the prevalence anemia its subtypes, as well interactions, in patients with type 2 diabetes (T2D).
Language: Английский
Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 209 - 209
Published: Jan. 24, 2025
Background and Objectives: Insulin resistance (IR) is a key factor involved in the development of type 2 diabetes (T2D). Besides its role pathogenesis T2D, insulin associated with impairment glycemic control, reduced achievement targets, increases cardiovascular risk complications, being thus negative prognosis factor. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are therapies for T2D which demonstrated, besides improvements biomarkers traditionally IR inflammation. This study aimed to evaluate impact SGLT2i treatment on inflammation patients T2D. Materials Methods: In retrospective study, 246 treated median 5 years were evaluated regarding (estimated glucose disposal rate—eGDR, triglyceride/glucose index, triglyceride/HDLc index) (neutrophils lymphocyte ratio, platelets lymphocytes ratio C-reactive protein) before after intervention SGLT2i. Results: After treatment, had higher eGDR (6.07 vs. 5.24 mg/kg/min; p < 0.001), lower (3.34 3.52, 0.001) index (9.23 9.58; 0.001). The decreased therapy: protein (3.07 mg/L 4.37 mg/L), NLR (0.68 0.72; PLR (115 122; Intervention also improved complications risk: HbA1c (7.1% 8.4%; body mass (30.0 31.5 kg/m2; urinary albumin creatinine (4.75 11.00 mg/g; Conclusions: Treatment leads decreases These mechanisms may partially explain additional renal reductions therapy, alongside
Language: Английский
Citations
0
Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(03), P. 35 - 41
Published: Jan. 1, 2025
Language: Английский
Citations
0
Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12
Published: March 5, 2025
Contrast-induced acute kidney injury (CIAKI) is a common and serious complication following contrast administration in patients undergoing percutaneous coronary intervention (PCI). dapagliflozin, sodium-glucose co-transporter 2 inhibitor (SGLT2i), has demonstrated renal protective effects various clinical settings. However, the impact of dapagliflozin on incidence CIAKI with type diabetes mellitus (T2DM) PCI not yet fully understood. To evaluate long-term prognosis T2DM PCI. This retrospective cohort study included who underwent at Department Cardiology, Tianjin University Chest Hospital, from January 2022 to June 2023. Patients were grouped based use (dapagliflozin vs. no dapagliflozin). Renal function was assessed before PCI, 48 h, 1 week post-PCI, measuring serum creatinine, estimated glomerular filtration rate, cystatin C, neutrophil gelatinase-associated lipocalin. All followed for least year. The primary endpoint incidence, secondary endpoints including changes major adverse cardiovascular events (MACE). occurred less frequently group compared control (5.8% 11.7%, χ2 = 4.494, p 0.033). After adjusting confounders, an independent predictor reduced risk (OR 0.365, 95% CI: 0.176-0.767, 0.008). During median 15-month follow-up, had lower MACE (Log-rank χ 6.719, 0.009). Cox regression analysis showed that (HR 0.484, 0.246-0.955, 0.036). Chronic can reduces improves outcomes These findings support its potential as adjunctive therapy mitigate improve this high-risk population.
Language: Английский
Citations
0
Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 1974 - 1974
Published: Dec. 1, 2024
Background and Objectives: Type 2 diabetes (T2DM) affects millions across the globe, generating a veritable public health issue through quality-of-life-reducing chronic complications, among which urinary tract infections are most common. A shift in disease managing paradigm from glucose-centered view to concept of cardio-reno-metabolic has uniquely placed SGLT2 inhibitors as viable medication for complex management T2DM its comorbidities. Some concerns have been raised over increased likelihood (UTIs) associated with inhibitor use. The current study aims evaluate risk developing if patients type take determine those factors make these more prone develop this undesired complication. Materials Methods: cross-sectional, noninterventional evaluation 328 consecutively admitted Diabetes Clinic “Pius Brinzeu” County Emergency Hospital Timisoara, between January February 2024, was performed by examining medical charts running statistical analyses using MedCalc version 22.26.0.0. Results: There no difference taking other glucose lowering medications when presence UTIs. Those higher HbA1c or BMI showed an predisposition contracting UTI. female gender also further sublot revealed that not only could be predictor UTI, but longer duration predisposing factor. Conclusions: use did increase infection patient population.
Language: Английский
Citations
0
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(23), P. 7306 - 7306
Published: Dec. 1, 2024
Anemia is a prevalent comorbidity of diabetes, and although various mechanisms have been shown to link these two conditions, their interaction has not sufficiently explored. Our cross-sectional, non-interventional study aimed evaluate the prevalence anemia its subtypes, as well interactions, in patients with type 2 diabetes (T2D).
Language: Английский
Citations
0